GLGC Gene Logic Inc. (MM)

Agreement with World's Largest Pharmaceutical Company Includes Success-Based Milestones plus Royalties on Repositioned Drug Candidates Gene Logic Inc. (NASDAQ: GLGC) announced today that it has entered into an agreement with Pfizer Inc. to seek new therapeutic indications for a significant number of unapproved drug candidates that are not currently in active development. The drug candidates originated from across Pfizer's portfolio of therapeutic areas. Similar to development stage in-licensing deals, the terms of the agreement provide for success-based milestones per compound and royalties on the commercialization of drugs repositioned through Gene Logic's Drug Repositioning Program. Full terms of the agreement were not disclosed. Gene Logic's Drug Repositioning Program seeks to restore stalled drug candidates back into its partners' clinical development pipelines. Applying a platform of diverse technologies in parallel, Gene Logic's program evaluates drug candidates for potential utility across a wide spectrum of disease indications. This platform represents the integration of technologies acquired from Millennium Pharmaceuticals Inc. in 2004 with Gene Logic's premiere capabilities in genomics and in silico biology. Gene Logic can complete initial repositioning testing and analysis in less than a year, potentially returning drug candidates expediently to clinical testing. Louis Tartaglia, Ph.D., general manager and senior vice president of Drug Repositioning for Gene Logic, said, "Gene Logic's Drug Repositioning Program will complement Pfizer's ongoing efforts in drug development. We will be putting Pfizer's selected drug candidates through a diverse battery of technologies specifically designed for drug repositioning. Data analysis from those studies will provide a comprehensive picture of the drug candidates' biological activities and determine possible new therapeutic uses for these potential medicines." Mark D. Gessler, chief executive officer and president of Gene Logic, remarked, "We are pleased to see our latest business validated through this partnership with the world's largest pharmaceutical company. Our goal with the drug repositioning business is to provide substantial value to our clients, and in return, share in the long-term success of their repositioned drugs through milestone and royalty payments. Working with Pfizer is an important step toward achieving that goal, and may have larger, transformative implications for populating the industry's late-stage pipelines." Gene Logic Overview Gene Logic aspires to be the most valued drug development partner for the pharmaceutical industry. Gene Logic applies its broad and unique mix of technologies, talent and methodologies to work on behalf of its partners to enable pharmaceutical and biotechnology companies to make more informed, more reliable and more predictive decisions at each point in the highly complex and costly drug development process. For more information, visit www.genelogic.com or call toll-free - 1/800/GENELOGIC.